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Abstract
Background: Highly active antiretroviral therapy (HAART) is recommended to control the infection of HIV-1. HIV-1
drug resistance becomes an obstacle to HAART due to the accumulation of specific mutations in the RT coding
region. The development of resistance mutations may be more complex than previously thought.
Methods: We followed two HIV-1 infectors from a HIV-1 drug resistance surveillance cohort in Henan province
and evaluated CD4+ T-cell number and viral load thereafter at ten time-periods and characterized their reverse
transcriptase-associated mutation patterns at each time point. Then we constructed the recombinant virus strains
with these mutation patterns to mimick the viruses and test the phenotypic resistance caused by the mutation
patterns on TZM-b1 cells.
Results: CD4+ T-cell number initially increased and then decreased rapidly, while viral load decreased and then
dropped sharply during initial antiretroviral treatment. The number of mutations and the combination patterns of
mutations increased over time. According to the phenotypic resistance performed by recombinant virus strains,
VirusT215Y/V179E/Y181C/H221Y exhibited high levels of resistance to EFV (5.57-fold), and T215Y/V179E-containing
virus increased 20.20-fold in AZT resistance (p < 0.01). VirusT215Y/V179E/Y181C increased markedly in EFV resistance
(p < 0.01). The IC50 for VirusT215Y/V179E/H221Y was similar to that for VirusT215Y/V179E/Y181C. VirusT215Y/K103N/
Y181C/H221Y induced a dramatic IC50 increase of all the four agents (Efavirenz EFV, Zidovudine AZT, Lamivudine
3TC, and Stavudine d4T) (p < 0.01). As for VirusT215Y/K103N/Y181C, only the IC50 of EFV was significantly increased.
T215Y/K103N resulted in a 26.36-fold increase in EFV (p < 0.01). T215Y/K103N/H221Y significantly increased the
resistance to AZT and 3TC. The IC50 of EFV with T215Y/V179E was lower than with T215Y/K103N (F = 93.10,
P < 0.0001). With T215Y/V179E, Y181C significantly increase in EFV resistance, while the interaction between
181 and 221 in EFV was not statistically significant (F = 1.20, P = 0.3052). With T215Y/K103N, neither H221Y
nor Y181C showed a significant increase in EFV resistance, but the interaction between 181 and 221 was
statistically significant (F = 38.12, P = 0.0003).
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Conclusions: Data in this study suggests that pathways of viral evolution toward drug resistance appear to
proceed through distinct steps and at different rates. Phenotypic resistance using recombinant virus strains
with different combination of mutation patterns reveals that interactions among mutations may provide
information on the impact of these mutations on drug resistance. All the result provides reference to
optimize clinical treatment schedule.
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Background
Highly active antiretroviral therapy (HAART) consists of
two nucleoside reverse transcriptase inhibitors (NRTIs)
plus a non-nucleoside reverse transcriptase inhibitor
(NNRTI) in China. It highly suppresses HIV-1 replica-
tion and reduces the morbidity and mortality associated
with HIV-1 infection and AIDS [1, 2]. However, HIV-1
drug resistance is becoming an obstacle to effective
long-term HAART due to the accumulation of specific
mutations in the reverse transcriptase (RT) coding re-
gion [3]. More than 200 mutations are associated with
antiretroviral resistance and HIV-1 drug resistance pro-
files continue to be updated [4–6].
Long-term, complicated antiretroviral regimens select
very complex viruses, including multi-drug resistant mu-
tations that are currently arcane [7]. Novel mutations
may actively participate in NNRTI resistance, and the
development of NNRTI resistance may be more complex
than previously thought (≥3 NNRTI resistance muta-
tions) [2]. Notably, multiple mutations do not accumu-
late randomly but appear to be orderly. Evolutionary
pathways and the patterns of multiple mutations have
been previously selected from a range of quasi-species
by drug-selective pressure [8, 9]. Primary NNRTI resist-
ance mutations are also well characterized [10, 11],
while, other secondary mutations usually occur in com-
bination with primary NNRTI resistance mutations;
whether such mutations further diminish drug suscepti-
bility remains unclear [12].
Various subtypes of HIV lead to features of antiretro-
viral therapy (ART) in China [13]. We applied a medical
model that unifies medicine and management of patients
by township health and the Centers for Disease Control
and Prevention (CDC). This endows HIV-1 drug resist-
ance strains with features distinctive to our country. Re-
sults of HIV-1 drug resistance surveillance in patients
who fail first-line antiretroviral therapy showed H221Y
usually accompanied the position mutations of T215Y,
K103N, Y181 of RT [14]. H221Y is reported to be
strongly associated with drug therapy [15], but its role is
not clear. Herein, we followed two patients so as to ob-
serve the order of appearance of resistance associated
mutations, and detected phenotypic sensitivity of recom-
binant virus that assumed related mutations. Finally, we
analyzed the role of H221Y in resistance to commonly
used drugs in China (Efavirenz EFV, Zidovudine AZT,
Lamivudine 3TC, and Stavudine d4T) and the interac-
tions between H221Y and Y181C.
Results
CD4+ T-cells and viral load
For patient 1, CD4+ T-cells increased after initial ther-
apy, especially in the 19th month, where the CD4+ T-cell
count was the highest (219 cells/μl). Subsequently, CD4+
T-cell number declined rapidly and dropped to lower than
50 cells/μl in the 31st month. The low CD4+ T-cell num-
bers continued to the end of the follow-up investigation in
the 55th month. However, HIV-1 viral load was main-
tained at a high level (>10000 copies/ml) since the 25th
month, at the same time that CD4+ T-cells began to de-
cline (Fig. 1a). Viral load was below the sensitivity of
Nuclisens® EasyQ kit in the 1st month, so we did not show
it in the figure. For patient 2, CD4+ T-cells remained at
150 cells/ μl until 30 months of treatment, and then began
to decline, dropping below 50 cells/ μl. Viral load was
greater than 104 copies/ml from the 36th month on, when
CD4+ T-cells began to decline rapidly (Fig. 1b). Viral load
was below the sensitivity of Nuclisens® EasyQ kit in the 6th
and 12th month.
Mutation patterns
A clonal sequencing approach was adopted in this study
in order to trace the pathway for mutations. We
obtained 372 clonal sequences in plasma, with 265
sequences from patient 1 plasma, other sequences
from patient 2 plasma. Clonal sequences in PBMC
were 197, with 111 sequences from patient 1 plasma,
other sequences from patient 2 plasma. These se-
quences contained different combinations of NRTI
and NNRTI resistance mutations.
For patient 1 (Fig. 1c), T215Y was the earliest NRTI
mutation to emerge in plasma in the 15th month of ther-
apy, followed by M41L and then by E44D. However,
E44A replaced E44D as the last pattern of mutation with
respect to M41L/T215Y. In PBMCs, it was M41L/E44D/
T215Y that was first detected in the 25th month; with
E44A replacing E44D completely by the following visit,
and M41L/E44A/T215Y was the last NRTI mutation
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pattern to be observed. Two mutation patterns, both
V179D and V179E, were observed in plasma and
PBMCs. V179D was found in plasma from the first
month; however, V179E began to replace V179D in the
25th month and completely replaced V179D in the 49th
month. V179D first emerged in PBMCs in the 7th
month, with only 12.5 %. V179E emerged in the 25th
month and completely replaced V179D in the 31st
month. In plasma, Y181C emerged in the 7th month,
followed by H221Y with 100 % mutation in the 15th
month. In PBMCs, Y181C combined with H221Y to
emerge in the 25th month and this then remained stable.
However, resistance in PBMCs occurred later than in
plasma.
Fig. 1 Viral Load (CD4 T cells) evolution, the different time-point, and the proportion of clones with none,single, double,…mutations in plasma
(in PBMCs) for the two patients. Viral load was below the sensitivity of Nuclisens® EasyQ kit in the 1st month for patient 1, so we did not show
the point in a. Viral load was below the sensitivity of Nuclisens® EasyQ kit in the 6th and 12th month for patient 2 and the two points were not
show the point in b. c, d showed the percentage of mutations in RT at each follow-up. Left, y-axis represents mutations in plasma and right,
y-axis represents mutations in PBMCs at the same time. Right, x-axis represents follow-up times
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For patient 2 (Fig. 1d), we did not gain an adequate
quality of sequences in PBMCs, but acquired clonal se-
quences with high viral load in the plasma sample. In
plasma from patient 2, numbers of mutations were very
low. T215Y, K103N, and Y181C were detected in plasma
with 100 % observed by the 30th month. H221Y emerged
with a low mutation percentage (19.20 %). And by the
following visit, virus K103N/Y181C/H221Y was associ-
ated the same percentage.
Phenotypic assays of drug susceptibility
Patients in this study were exposed to both NRTI and
NNRTI (AZT plus ddI plus NVP). The last stable muta-
tion pattern observed in both patients’ plasma and in
PBMCs was the double-mutation Y181C/H221Y, along
with others (Fig. 1c, d). We detected the phenotype of
the last mutation patterns by recombining patient-
derived HIV fragments into a pNL4-3 plasmid. Herein,
we then examined the impact of mutations on AZT anti-
retroviral therapy. EFV, 3TC, and d4T were not used in
the two patients, but are commonly used in HAART in
China.
We constructed a recombinant virus by site-directed
mutagenesis to analyze impacts of drug susceptibility.
We obtained eight recombinant viruses: T215Y/V179E/
H221Y/Y181C, T215Y/V179E/Y181C, T215Y/V179E/H2
21Y, T215Y/V179E, T215Y/K103N/H221Y/Y181C, T215Y/
K103N/Y181C, T215Y/K103N/H221Y, and T215Y/K103N.
Table 1 shows the mean ± SD of IC50s from three inde-
pendent experiments and the fold-change in IC50 (FC, cal-
culated by dividing the IC50 for each mutant virus by the
IC50 for the wild-type).
As shown in Table 1, virusT215Y/V179E/Y181C/H221Y,
the recombined patient-derived HIV-1 RT fragment, did
not exhibit a significant increase with respect to AZT re-
sistance, but did exhibit higher levels of resistance to EFV
(up to 5.57-fold). However, it did not enhance resistance
greatly to the other two NRTIs tested. T215Y/V179E-con-
taining virus resulted in a dramatic 20.20-fold increase in
AZT resistance (p < 0.01), and a second increase in 3TC
and d4T (P < 0.05). Virus with a triple-mutation of
T215Y/V179E/Y181C manifested an observed increase in
AZT, 3TC, and d4T resistance (p < 0.05). In addition, this
virus also resulted in a dramatic increase in EFV resistance
(p < 0.01). With respect to EFV and 3TC effects, patients
were not to take medicine in follow-up investigations. The
IC50 of different drugs for another triple-mutation,
T215Y/V179E/H221Y, presented an effect similar to that
with T215Y/V179E/Y181C, but at a different level of sig-
nificance. Resistance was highly significantly increased
with respect to AZT, 3TC, and d4T (p < 0.01), while re-
garding EFV, this increase was significant at the p < 0.05
level.
VirusT215Y/K103N/Y181C/H221Y, the HIV-1 RT frag-
ment from patient 2, exhibited dramatic increases in
IC50 with respect to all the four agents (AZT, 53.94-fold;
EFV, 33.79-fold; 3TC, 31.72-fold; d4T, 37.72-fold; p <
0.01). However, when H221Y was reversed (T215Y/
K103N/Y181C), only the IC50 of EFV was observed to
significantly increase to 122.07 ± 12.24 nM (8.19-fold,
p < 0.01), although this was lower than the 503.47 ±
207.80 nM (33.79-fold). T215Y/K103N resulted in a
26.36-fold increase in EFV (p < 0.01). When we added
H221Y, the T215Y/K103N virus significantly increased
its AZT and 3TC resistance.
Contributions to drug resistance of mutations
First, we analyzed the resistance contribution of the
background mutations. P ≤ 0.01 was considered to be
statistically significant. The resistance contribution of
background mutations was not statistically significant
with respect to AZT, 3TC or d4T (F = 1.79, P = 0.1968,
Table 1 IC50s for 5 viruses and comparison of FC and pNL4-3wt
Virus EC50
a ± SD (nM) (FCb)
NNRTIs NRTIs AZT EFV 3TC d4T
WTpNL4-3 24.80 ± 12.83 14.90 ± 0.35 25.46 ± 3.90 197.87 ± 7.93
V179E/Y181C/H221Y T215Y 273.43 ± 108.18(11.02) 83.04 ± 25.00 (5.57)** 427.03 ± 225.85 (16.77) 880.20 ± 299.01 (4.04)
V179E/Y181C T215Y 382.50 ± 216.51 (15.42)c 62.94 ± 3.58 (4.23)** 622.10 ± 82.10 (24.43)** 1048.73 ± 229.18 (5.30)c
V179E/H221Y T215Y 1950.67 ± 688.66 (78.65)** 52.48 ± 3.44 (3.52) c 1304.30 ± 304.75 (51.22)** 2170.00 ± 494.11 (10.97)**
V179E T215Y 501.00 ± 95.98 (20.20)** 34.41 ± 11.97 (2.31) 240.77 ± 34.68 (9.46)c 1031.33 ± 350.34 (5.21)c
K103N/Y181C/H221Y T215Y 1337.67 ± 89.49 (53.94)** 503.47 ± 207.80 (33.79)** 807.70 ± 123.88 (31.72)** 7462.67 ± 900.25 (37.72)**
K103N/Y181C T215Y 52.78 ± 6.79 (2.13) 122.07 ± 12.24 (8.19)** 139.67 ± 41.81 (5.49) 420.60 ± 125.31 (2.13)
K103N/H221Y T215Y 1393.00 ± 100.80 (56.17)** 154.63 ± 30.80 (10.38)** 264.73 ± 42.13 (10.40)** 422.27 ± 46.19 (2.13)
K103N T215Y 88.00 ± 12.48 (3.55) 392.70 ± 74.88 (26.36)** 141.60 ± 62.63 (5.56) 471.93 ± 66.35 (2.39)
athe 50 % inhibitory concentration
bcalculated by dividing the IC50 of each mutant virus by the IC50 for the wild-type. Mean ± SD of three independent experiments
cIC50 was significantly changed compared with pNL4-3wt
P < 0.05; “**” denotes P < 0.01
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F = 7.19, P = 0.0148 and F = 4.99, P = 0.0376) (Table 2).
However, the IC50 for virus incorporating Y181C was
higher than the others without Y181C with respect to
AZT and 3TC (P < 0.0001 and P = 0.0010); while
Y181C did not increase the IC50 of d4T (F = 4.99, P =
0.0719). H221Y did not affect the IC50 of three NRTIs
(AZT, 3TC, and d4T). The interaction between the
two sets was not statistically significant for AZT, 3TC,
and d4T.
For EFV, the IC50 for virus with the T215Y/V179E
mutation was higher than with T215Y/K103N, sug-
gesting that the background factor affected the IC50
significantly (F = 93.10, P < 0.0001). Regarding T215Y/
V179E as the background, Y181C expressed signifi-
cant increases in EFV resistance, but H221Y did not.
The interaction between 181 and 221 in EFV was also
not statistically significant (F = 1.20, P = 0.3052). In a
T215Y/K103N background, neither H221Y nor Y181C
expressed significant changes in EFV resistance (F = 0.12,
P = 0.7404 and F = 4.24, P = 0.0736), but the interaction
between 181 and 221 was statistically significant (F =
38.12, P = 0.0003).
Discussion
We observed the dynamic changes in CD4+ T-cell num-
ber and viral load from the start of therapy. During the
first 20 months approximately, therapy may be effective,
with corresponding changes in CD4+ count and viral
load. However, therapy may fail from the 20th month on.
Viral load increased markedly and CD4+ T-cell count
dropped rapidly in our study. One possible explanation
for the effectiveness of HAART is that mutations that
confer resistance to one drug class can increase the sus-
ceptibility of viruses to other classes [16, 17]. However,
resistance mutations did not emerge individually, but ra-
ther in a combined fashion.
We detected the RT genotype of the virus in plasma
and PBMCs at every follow-up visit, and we analyzed the
mutations that emerged in plasma and PBMCs using
clonal sequencing. No mutations were shown during
43–55 months in patient 1 because we did not acquire a
sufficient number of sequences due to so few PBMCs
being present. However, related mutations emerged in
PBMCs later than in plasma as in a previous study [18].
Herein, T215Y and V179D were observed in plasma first
compared to PBMC, as with Y181C. However, different
pathways were displayed in plasma and PBMCs. In
plasma, emergence of H221Y followed Y181C for about
one half–year, but was combined with Y181C in PBMCs.
Overall, we observed a change in not only the number
of mutations over time (from less to more, then to less),
but also in the specific combination of mutations that
evolved (to achieve stable for about 48 months). At the
end of the current investigation, we found that the mu-
tation at 179 exited stably with V179E, but not initially
with V179D. It is reported that a differential genetic bar-
rier was found for V106M, V108I, P225H in different
HIV-1 subtypes for NNRTI resistance-related substitu-
tions [19]. It may be the reason for the phenomenon of
V179D/E. Resistance mutations usually are polymorphic,
and include at least two nucleotides. The changing of
amino acid spatial structure affect the affinity of drugs
and target to cause resistance. This may be another rea-
son for more stable of V179E than V179D. However, the
last patterns of correlated mutations may be the result
of pharmacologic pressure imposed by the drug regi-
mens [2, 7]. This suggests that other treatment regimens
may lead to the development of pathways that are par-
tially different from those that we observed. In 1994,
Larder summarized a series of mutations associated with
T215Y and the sequential appearance of these changes
[20]. This report indicated that K70R was followed by
T215Y and accumulated the cluster mutation M41L/
D67N/K70R/T215Y (K219Q), but herein we observed
no cluster. We rather considered H221Y as a novel mu-
tation along with Y181C.
Table 2 Results of statistical analysis of resistance contributed by different sets
Name of
drug
Background mutations factora P (Single seatb) P (Interaction(181*221)c)
F value P 181 221 T215Y/V179E T215Y/K103N
EFV 93.10 <0.0001 0.0002 (F = 43.20)d 0.0598 (F = 4.80)d 0.3052 (F = 1.20)d 0.0003 (38.12)e
0.7404 (F = 0.12)e 0.0736 (F = 4.24)e
AZT 1.79 0.1968 <.0001 (F = 25.84) 0.018 (F = 6.69) 0.2270 (F = 1.56)f
3TC 7.19 0.0148 0.0010 (F = 14.94) 0.5356 (F = 0.40) 0.2513 (F = 1.40)
d4T 4.99 0.0376 0.0719 (F = 4.99) 0.4400 (F = 0.62) 0.2269 (F = 1.56)
aAnalyze if it is statistical significance between the impact of T215Y/V179E and T215Y/K103N on the IC50 of different drugs. Here, T215Y/V179E and T215Y/K103N
are the background mutations factors
bAnalyze the impact of single mutations (Y181C or H221Y) on the IC50 of different drugs
cAnalysis of the interaction between 181 and 221 on the different background mutations factors. Due to the difference is significant of impact of T215Y/V179E
and T215Y/K103N on EFV (F = 93.10, P < 0.0001)
dand eanalyze the interaction between 181 and 221 on the background of T215Y/V179E and T215Y/K103N respectively. f is the P of the interaction between 181
and 221 ignoring the background mutations on different drugs
P ≤ 0.01 was considered to be statistically significant
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More complex combinations of RT mutations confer
more complex co-resistance. A study detected that mul-
tiple mutations (K103N/Y181C/H221Y, K103N/Y181C,
K103N/H221Y) significantly increased NVP resistance
[21]. Herein, we determined the impact of associated
mutations with respect to AZT medications taken by
patients, d4T (with the same resistance mechanisms as
AZT), 3TC (whose resistance mechanisms were in-
creased with reference to RT discrimination properties
[22]), and EFV. Classical key mutations (TAMs, M184V,
K103N and so on) recruited in HIV drug resistance
database are responsible for either drug-specific resist-
ance or cross resistance; and along with these, viral
strains demonstrate non-canonical changes in treated
patients whose contribution to the phenotype is un-
known [20]. T215Y, a classical mutation, is suggested to
cause AZT and d4T resistance; and V179D/E is consid-
ered to be an NNRTI mutation, by itself reducing NVP
and EFV susceptibility approximately 2-fold [23]. In the
present study, we detected the contribution to AZT,
3TC, d4T and EFV resistance by the double mutation
T215Y/V179E. Our results showed that the co-presence
of T215Y/V179E significantly increased AZT and d4T
resistance respectively. However, we could not sure if
the effect of single V179E is important and further re-
search about role of V179E is needed. However, V179E
is associated with low-level resistance to EFV in HIV
drug resistance database [23]. But resistance to EFV of
T215Y/V179E is not significant in our study. This may
be affected by T215Y. It is not reported that T215Y is
associated with resistance of 3TC [23]. We found resist-
ance of T215Y/V179E to 3TC was significant and this
may be affected by V179E.
H221Y is a nonpolymorphic accessory NNRTI-selected
mutation that usually occurs in combination with Y181C
[24]. It is frequently selected in patients receiving rilpivr-
ine (RPV) [25]. Alone H221Y has minimal detectable ef-
fects on NNRTI susceptibility [26]. According to the
mutation patterns that emerged in plasma, i.e., Y181C
followed by H221Y. We separately compared the resist-
ance of T215Y/V179E/Y181C and T215Y/V179E/Y181C/
H221Y to the wild-type virus. The triple-mutation T215Y/
V179E/Y181C led to a dramatic increase in resistance in
the wild-type virus to all four drugs evaluated. However,
T215Y/V179E/Y181C/H221Y only resulted in a marked
increase in EFV. H221Y slightly decreased T215Y/V179E/
Y181C resistance to AZT, d4T and 3TC. With respect to
EFV, Y181C, and H221Y both showed increased resist-
ance. However, these sets of resistance mutations (Y181C/
H221Y) conferred cross-resistance to all three NRTIs.
Y181C is a nonpolymorphic mutation selected in vitro by
NNRTIs (NVP, EFV, RPV and ETR) and it is not reported
relating to NRTIs. We found Y181C attenuated resistance
of T215Y/V179E to AZT, but it was not significant.
Additionally, Y181C did not modify resistance of T215Y/
V179E to d4T and led to an increase in the mean IC50
value from 240.77 ± 34.68 nM for T215Y/V179E to
622.10 ± 82.10 nM for the triple-mutation with respect to
3TC.
T215Y is interpreted to be resistant to AZT and d4T;
and its co-presence with K103N, a mutation to the first-
generation NNRTI, did not increase the IC50 with re-
spect to AZT and d4T. In other words, K103N may
compensate resistance as a result of T215Y with respect
to AZT and d4T. Adding Y181C to T215Y/K103N
lowered the IC50 of AZT to insignificance. Y181C and
H221Y also decreased the impact of T215Y/K103N on
EFV, and their combination with T215Y/K103N
augmented the IC50 of EFV. To confirm the role of
Y181C, H221Y and any interaction between them, we
analyzed the results of IC50s using appropriate statistical
methods. We first analyzed the impact of background
mutations on the various agents. Results showed that
there was no difference in the IC50s of AZT, 3TC, or
d4T between T215Y/V179E and T215Y/K103N. It is
likely that effect of T215Y predominates as regards the
resistance to AZT, 3TC, and d4T. The IC50 of virus in-
corporating T215Y/K103N was higher than the virus
with T215Y/V179E (P < 0.0001). One possible explan-
ation for this is that the impact of K103N on EFV resist-
ance may be greater than that of V179E. We therefore
analyzed the contribution of the single mutations Y181C
and H221Y. Y181C was demonstrated to decrease the
IC50s of AZT and 3TC, and H221Y increased the IC50
of AZT. Y181I/C, which constituted NVP-selected mu-
tations, was reported not only to confer cross-resistance
to d4T [27, 28], but also to improve sensitivity to AZT
[20]. Herein, we did not obtain an effect of Y181C with
respect to d4T. However, interaction between the two
sites was not significant. For EFV, only Y181C increased
the IC50 in a T215Y/V179E background. Contribution
to resistance for H221Y was insignificant compared with
Y181C. Dramatically, Y181C and H221Y expressed
synergism in a T215Y/K103N background of. Patients
should adjust therapy regimen as quickly as possible for
better result once T215Y/K103N/Y181C/H221Y emer-
ging. Since contributions to resistance for multiple mu-
tations were not geometrically additive, it is conceivable
that a greater number of mutations or associated muta-
tions than are currently known are involved in the devel-
opment of drug resistance [7]. How these mutations
cause resistance and alter replicative capacity is unclear.
Future studies will be necessary to better elucidate and
highlight their mechanisms of action both in vitro and in
vivo. Along with more complex patterns, it is more dif-
ferent to mastery the mechanism of resistance and repli-
cation. Although, viral evolution pathways toward drug
resistance may proceed through distinct steps and at
Guo et al. Virology Journal  (2015) 12:187 Page 6 of 9
different rates among different HIV-1 subtypes [8]. To
study the interaction between different mutations is con-
tribute to partly understand the pathways of mutation
patterns under different drugs pressure. However, similar
evaluation in more subtypes B’ and other non-B’ sub-
types phenotypic test of HIV-1 is necessary, because of
data in this study based on a recombine of subtype B’
and pNL4-3 wild-type. Furthermore, not only alterations
in RT function of a mutation may contribute to resist-
ance and replication, but interaction between mutations
give some information on the impact of these mutations
on virus replication and drug resistance.
Conclusions
Data in this study suggests that pathways of viral evolu-
tion toward drug resistance appear to proceed through
distinct steps and at different rates among HIV-1 infec-
tors. Phenotypic resistance using recombinant virus
strains with different combination of mutation patterns
reveals that interactions among mutations may provide
information on the impact of these mutations on drug




Two patients from a HIV-1 drug resistance surveillance
cohort in Henan province were selected after informed
consent. Data revealed that they are of Han ethnicity
and not habituated to alcohol. The two male patients
were infected with HIV-1 by commercial plasma collec-
tion and their infections were validated in July of 2003.
They were given regimens of NRTIs plus NNRTIs [AZT
plus Didanosine (ddI) plus Nevirapine (NVP)] in Sep-
tember, and we have followed them for ten time-periods
over 55 months, with intervals of five to six months
each. We collected 10 ml samples of anti-coagulated
whole blood each time, centrifuged the samples to ob-
tain plasma and peripheral blood mononuclear cells
(PBMCs), and stored them at -80 °C. Patient 1 (35 years
old) complied with treatment regimens well, while pa-
tient 2 (45 years old) discontinued the drugs during the
follow-up periods.
CD4+ T cell and plasma HIV-1 viral load
A flow cytometer (FACSCalibur, BD, America) was used
to count CD4+ T cells according to the manufacturer’s
instructions, using BD TriTESTT[M] CD3FITC/CD4PE/
CD45PerCP for fluorescence labeling. Plasma HIV-1
viral loads were measured by Nucleic Acid Sequence
Based Assay (NASBA) according to Nuclisens® EasyQ kit
(BioMerieux, France) instructions.
Clonal sequencing of HIV-1 in plasma and PBMCs
Clonal sequencing was performed according to reference
[29]. RNA and DNA were extracted from plasma and
PBMCs as templates for nested PCRs, respectively. RNA
and DNA were amplified using outer primers PLA-1/
PLA-2 and inner primers PLA-3/PLA-4 [14, 17]. PCR
products (2.1 kb, HXB2: 2147-4308 bp) were independently
cloned into pMD-18 T, and a single clone was sequenced.
Each sequence reflected the genotype of an independent
viral genome. To track the mutation patterns, we analyzed
sequences from each follow-up time.
Recombinant virus construction and viral stocks
preparation
Recombinant virus was constructed as previously de-
scribed [21]. Site-directed mutagenesis was carried out to
reverse H221Y and/or Y181C of pMD-18 T, which har-
bored T215Y/V179E/Y181C/H221Y and T215Y/K103N/
Y181C/H221Y, respectively. A 643 bp HIV-1 RT fragment
(HXB2: 2843 nt-3485 nt) was obtained by Age I (A/
CCGGT) and Sbf I (CCTGCA/GG), and this replaced
the corresponding sequence in pNL4-3 pol. The fol-
lowing mutations were introduced into RT of recombin-
ant pNL4-3 plasmids: T215Y/V179E/Y181C/H221Y, T215
Y/V179E/Y181C, T215Y/V179E/H221Y, T215Y/V179E,
T215Y/K103N/Y181C/H221Y, T215Y/K103N/Y181C, T2
15Y/K103N/H221Y, and T215Y/K103N. Recombinant
pNL4-3 wild-type (pNL4-3wt) and mutant viruses were
generated by the transfection of the corresponding plas-
mid DNAs into HEK293T cells using Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen,
America). Transfection supernatants were harvested at
48 h post-transfection and infected MT-2 cells and viral
cultures were grown in 4 to 6 days. Supernatants were
stored at -80 °C and the presence of the desired mutations
was verified by amplification and sequencing.
Phenotypic drug susceptibility assays
Phenotypic susceptibility analysis of the RT inhibitors
(EFV, AZT, 3TC, and d4T) was performed with recombin-
ant viruses in TZM-b1 (JC53) cells as described previously
[18]. Briefly, drugs at various concentrations were added
to TZM-bl cells (104 cells/well) in 96-well plates and cells
were grown in 100 μl of Dulbecco’s minimal essential
medium (DMEM; Gibco, America) supplemented with
10 % fetal bovine serum (Gibco, America) and 1 %
penicillin-streptomycin [30]. Immediately after drug
addition, cells were infected with pNL4-3wt or mutant vi-
ruses normalized by a 50 % tissue culture infectious dose
(TCID50). After virus and cells were co-cultured for 48 h at
37 °C in 5 % CO2 in compressed air, relative luminescence
units (RLU)/well were measured using a luminometer
(Wallik 1420; Perkin Elmer, America) according to the
Bright-GloTM Luciferase assay system (Promega E2650,
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Promega, America) instructions. The 50 % inhibition
concentration (IC50) was calculated using GraphPad Prism
(GraphPad Software, Inc. America) by plotting inhibition
curves of the percentage of inhibition of luciferase activity
versus log10 drug concentration [31, 32].
Statistical analysis
We used multiple testing statistical methods to assess
the IC50 differences between pNL4-3wt and mutant vi-
ruses and a nonparametric test was used for corrections.
We used quantitative data hypothesis testing in a factor-
ial design to analyze the role of H221Y and the interac-
tions between 181 and 221. A false discovery rate of 0.05
was used to determine statistical significance. P ≤ 0.01
was considered to show statistical significance among
mutational viruses. Analyses were performed using SAS
(SAS Institute, Inc., America).
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